Obesity and obstructive sleep apnea (OSA) are strongly connected conditions that significantly affect morbidity and mortality worldwide. Recurrent airway blockage during sleep is a hallmark of OSA, which is frequently made worse by being overweight, especially by fat deposits around the neck that constrict the airway. This syndrome is associated with a higher risk of heart disease, daytime weariness, and fragmented sleep. The potential option for treating obese conditions and its related problems, such as OSA, is tirzepatide, a new bivalent agonist that targets the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Tirzepatide has been shown in clinical trials to greatly aid in weight loss; over a 72-week period, reports show reductions in body weight of up to 22.4%. Improved metabolic parameters, such as increased insulin sensitivity and decreased inflammatory markers, are correlated with this significant weight loss. According to research, the apnea-hypopnea index (AHI), a crucial indicator of the severity of OSA, might significantly decline with even modest weight loss. Tirzepatide has been proven in studies to significantly lower AHI; one research found that the drug reduced AHI by an average of -29.3 occurrences per hour when compared to a placebo. In addition to increasing insulin secretion, which improves glycemic control, tirzepatide also reduces hunger through pathways in the central nervous system, which makes weight management easier. Tirzepatide's mode of action is especially pertinent to obesity and OSA since it targets weight gain and metabolic dysregulation, two important contributors in the onset and aggravation of sleep apnea. Tirzepatide's novel mechanism, clinical effectiveness in encouraging weight reduction and reducing the severity of OSA, and the close connection between obesity and OSA are all highlighted in this review, indicating that it may be a game-changing treatment for this dual health issue.
Naseem et al. (Thu,) studied this question.